It looks like you're using an Ad Blocker.

Please white-list or disable AboveTopSecret.com in your ad-blocking tool.

Thank you.

 

Some features of ATS will be disabled while you continue to use an ad-blocker.

 

Report on one PhIII remdisivir study sends investors into overdrive

page: 1
4

log in

join
share:

posted on Apr, 19 2020 @ 02:07 PM
link   
10 hours ago

Report on one PhIII remdisivir study sends investors into overdrive, adding billions to Gilead's market cap

Before any drug is officially proven effective against Covid-19, every data nugget surrounding an experimental treatment understandably arouses investors’ and patients’ hopes alike. Thursday night saw perhaps the most vivid and dramatic illustration to date.


Gilead shares $GILD soared 12.10% to $85.80 after STAT reported on one portion of the data from one of the company’s two ongoing Phase III trials for remdesivir. Of 125 patients recruited at the University of Chicago Medicine, 113 had severe disease and most of them have been discharged. Two deaths were recorded.



Is this is how you put a high case fatality rate back down to around 2 % ?

link



edit on 19-4-2020 by DoctorBluechip because: (no reason given)



posted on Apr, 19 2020 @ 10:18 PM
link   
They make a lot of money hacking nature's remedies and making expensive meds that do the same thing.



posted on Apr, 20 2020 @ 06:43 PM
link   
I hope it works. If this works for viruses in general it could be a big step in helping mitigate the next big outbreak.



 
4

log in

join